BridgeBio Oncology Therapeutics, Inc. (BBOT)

NGM – Real vaqt narxi. Valyuta: USD

9.22

+0.02 (0.22%)

Bozor ochiq: Aug 12, 2026, 11:55 AM EDT

9.10

-0.10 (-1.09%)

Oldingi bozordan keyin: Aug 11, 2026, 5:59 PM EDT

11.08.2026

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on August 10, 2026 under BBOT's 2025 Inducement Plan as a material inducement to the employment of two individuals hired by BBOT in July 2026.

11.08.2026

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Continued to advance monotherapy and combination cohorts for all clinical programs Initiated dosing of BBO-11818 in combination with cetuximab and after the end of the quarter, initiated dosing of BBO-11818 in combination with BBO-10203 Presented preclinical data at AACR highlighting the potency and activity of BBO-11818 in KRAS mutant tumor models and the efficacy of BBO-10203 in combination with tucatinib and trastuzumab in HER2amp models Cash runway expected to fund operations into 2028 SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.

Videolar

No Data

There is no data to display

Press-relizlar

11.08.2026

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

11.08.2026

BridgeBio Oncology Therapeutics, Inc. (BBOT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

BridgeBio Oncology Therapeutics, Inc. (BBOT)

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Videolar

No Data

Press-relizlar

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Videolar

No Data

Press-relizlar

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Search stocks

BridgeBio Oncology Therapeutics, Inc. (BBOT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

BridgeBio Oncology Therapeutics, Inc. (BBOT)

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Videolar

No Data

Press-relizlar

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Videolar

No Data

Press-relizlar

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress